Longeveron
Logotype for Longeveron Inc

Longeveron (LGVN) investor relations material

Longeveron Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Longeveron Inc
Q3 2026 earnings summary12 Nov, 2026

Executive summary

  • Laromestrocel remains the lead investigational therapy across four potential indications; strategic and financing alternatives, including a potential business combination, are under review with Lucid Capital Markets as advisor.

  • ELPIS II missed its primary HLHS efficacy endpoint; an updated analysis found fewer adjudicated events and a statistically significant MACE difference, and an FDA meeting was requested to discuss next steps.

Financial highlights

  • Q3 2026 revenue was $115K vs. $137K YoY; gross profit was $71K vs. $125K, with lower contract manufacturing revenue contributing to the decline.

  • Q3 operating loss was $7.2M vs. $7.3M; net loss was $6.1M vs. $7.2M, reflecting $1.0M of XPRIZE Healthspan award income and lower G&A expense.

  • 9M 2026 revenue was $800K vs. $834K; operating loss was $18.1M vs. $17.9M and net loss was $16.9M vs. $17.3M.

  • 9M operating cash use was $12.7M; financing provided $15.5M, lifting cash by $2.6M to $7.2M at September 30, 2026.

Outlook and guidance

  • Cash and cash equivalents of $7.2M were expected to fund operations into Q1 2027 under current plans and cash-conservation measures; additional capital will be needed to advance development.

  • Strategic alternatives may include a partnership or investment, additional financing, a sale or merger, or a business combination; no definitive timeline or assured outcome was established.

  • HLHS next steps depend on FDA review of ELPIS II; proposed AD Phase 2/3 and pediatric DCM trial plans depend on partnerships, funding and strategic review.

  • Forecasts show insufficient cash to meet minimum expenditure commitments for one year from financial-statement issuance; substantial doubt exists about the ability to continue as a going concern.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Longeveron earnings date

Logotype for Longeveron Inc
Q4 202626 Feb, 2027
Longeveron
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Longeveron earnings date

Logotype for Longeveron Inc
Q4 202626 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Longeveron Inc. is a clinical-stage biotechnology company focused on the development of cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational products are based on allogeneic mesenchymal stem cells (MSCs), which aim to promote tissue repair, reduce inflammation, and enhance immune responses. Longeveron’s research targets indications such as aging-related frailty, cardiovascular diseases, and other chronic conditions. The company is headquartered in Miami, Florida, and its shares are listed on the NASDAQ.